CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Corticosteroids - topical (skin), nose, and eyes - Management
Basis for recommendation
The recommendations for minimizing adverse effects are based on published expert opinion [Coulson, 1996], a manufacturer's Summary of Product Characteristics [ABPI Medicines Compendium, 2007], the British National Formulary [BNF 59, 2010], and a drug reference database [Sweetman, 2009].
- Topical corticosteroids should not be applied with an occlusive dressing to large areas of the body, as there is a high risk of systemic absorption and adverse effects [Sweetman, 2009].
- Occlusive dressings substantially increase the systemic absorption of topical corticosteroids [ABPI Medicines Compendium, 2007].
© NHS Institute for Innovation and Improvement